WHY IT MATTERS: Veterans currently using cannabis or pursuing psychedelic therapy outside the VA system risk losing continuity of care, benefits eligibility concerns, and lack of clinical supervision that a formal federal program would provide. CLINICAL OVERVIEW: Veterans organizations are pressing Congress to broaden access to both cannabis and psychedelic-assisted therapies through the VA system as a response to the persistently high suicide rate among veterans. The push reflects growing clinical evidence that current pharmacological and psychological treatment options are failing a significant portion of this population, particularly those with treatment-resistant PTSD and co-occurring substance use disorders.
Study: CBD-Dominant Cannabis Products Provide Significant Anxiety Relief – NORML
WHY IT MATTERS: Patients managing anxiety who are curious about cannabis now have additional research supporting CBD-dominant products as a potentially effective option worth discussing with a knowledgeable clinician before making any changes to current treatment. CLINICAL OVERVIEW: CBD-dominant cannabis products are gaining clinical attention as a potential option for anxiety management, with research suggesting meaningful symptom relief in patients who use formulations where cannabidiol predominates over THC. The anxiolytic properties of CBD are thought to involve serotonergic signaling and modulation of the endocannabinoid system, particularly at CB1 receptors and 5-HT1A receptors, which distinguishes its mechanism from both benzodiazepines and SSRIs.